文献速递神经肿瘤

CRYM通过抑制TGFβ1/Smad-EMT信号通路抑制胶质母细胞瘤进展

CRYM suppresses glioblastoma progression by inhibiting the TGFβ1/Smad-EMT signaling pathway.
PubMed 文献 · J Neurooncol · 2026-04-13

本研究探讨CRYM基因在胶质母细胞瘤(GBM)中的表达、功能及机制。采用qRT-PCR和Western blot检测CRYM在正常细胞与多种胶质瘤细胞系、正常脑组织与不同级别胶质瘤组织中的差异表达,并通过质粒转染过表达CRYM后利用CCK-8、Transwell、划痕愈合和EdU实验评估细胞增殖与侵袭,结合TGFβ1激动剂和WB阐明机制,并在裸鼠皮下异位及颅内原位移植模型中验证。结果显示CRYM在胶质瘤细胞系和临床胶质瘤组织中表达显著下调且随级别升高递减,过表达CRYM可显著抑制GBM细胞增殖和侵袭及体内肿瘤生长,其抑癌作用主要通过抑制TGFβ1/Smad信号通路和上皮-间质转化(EMT)实现。

要点

  • CRYM在胶质瘤细胞系和临床胶质瘤组织中表达下调,且随胶质瘤级别升高进行性降低。
  • 过表达CRYM可显著抑制GBM细胞体外增殖和侵袭,并在裸鼠皮下及颅内移植模型中抑制肿瘤生长。
  • CRYM抑癌作用主要通过抑制TGFβ1/Smad信号通路和EMT实现,提示其可能作为GBM治疗靶点及诊断预后生物标志物。

核心结论

  • CRYM高表达通过抑制TGFβ1/Smad信号通路和EMT显著抑制GBM进展,提示CRYM可能作为GBM的潜在治疗靶点。
  • CRYM也可能作为GBM诊断和预后的有前景的生物标志物。

研究设计与样本

  • 基础实验研究:采用qRT-PCR和Western blot检测正常细胞与多种胶质瘤细胞系、正常脑组织与不同级别胶质瘤患者肿瘤组织中CRYM的差异表达。
  • 通过质粒转染在多种胶质瘤细胞系中过表达CRYM,采用CCK-8、Transwell、划痕愈合和EdU实验评估其对胶质瘤细胞的作用。
  • 利用Western blot和TGFβ1激动剂阐明CRYM在GBM中的机制。
  • 动物体内实验采用裸鼠皮下异位及颅内原位胶质瘤移植模型验证CRYM过表达对GBM增殖的抑制作用。

主要发现

  • 与正常细胞系相比,CRYM在胶质瘤细胞系中表达显著下调。
  • 临床胶质瘤组织样本中CRYM水平低于正常脑组织,且随胶质瘤级别升高表达进行性降低。
  • 过表达CRYM在体外显著抑制GBM细胞增殖和侵袭。
  • 体内实验中,CRYM过表达在皮下异位和颅内原位移植模型中均显著抑制肿瘤生长。
  • 生物信息学分析和Western blot显示CRYM主要通过抑制TGFβ1/Smad信号通路和EMT发挥抑癌作用。

临床怎么用

  • CRYM低表达与胶质瘤级别升高相关,可作为潜在的诊断和预后生物标志物进行进一步临床验证。
  • 靶向CRYM或恢复其表达可能成为GBM治疗策略,其机制与抑制TGFβ1/Smad通路和EMT相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The role and mechanism of the CRYM gene in glioblastoma (GBM) remain unknown to date. Therefore, this study aims to report the abnormal expression of CRYM in glioblastoma and elucidate its function and underlying mechanism in GBM. METHODS: Using quantitative polymerase chain reaction (qRT-PCR) and western blotting(WB), we investigated the differential expression levels of CRYM between normal cells and various glioma cell lines, as well as between normal brain tissues and tumor tissues from patients with different grades of glioma. After overexpressing CRYM in various glioma cell lines via plasmid transfection, we demonstrated the role of CRYM in glioma cells through CCK-8, Transwell, wound healing, and EdU assays. The mechanism of CRYM in glioblastoma was elucidated using WB and a TGFβ1 agonist. In animal in vivo experiments, we further revealed the inhibitory effect of CRYM overexpression on glioblastoma proliferation in nude mice via subcutaneous ectopic and intracranial orthotopic glioma transplantation models. RESULTS: The results demonstrated that CRYM expression was significantly downregulated in glioma cell lines compared to normal cell lines. Similarly, clinical glioma tissue samples exhibited lower CRYM levels than normal brain tissues, with expression decreasing progressively as glioma grade increased. Overexpression of CRYM markedly suppressed the proliferation and invasion of GBM cells in vitro. These findings were further corroborated by in vivo models, wherein CRYM overexpression significantly inhibited tumor growth in both subcutaneous ectopic and intracranial orthotopic xenograft assays. Bioinformatic analysis and WB revealed that CRYM exerts its tumor-suppressive effects primarily by inhibiting the TGFβ1/Smad signaling pathway and epithelial-mesenchymal transition (EMT). CONCLUSION: High expression of CRYM significantly suppresses GBM progression by inhibiting the TGFβ1/Smad signaling pathway and EMT, suggesting CRYM as a potential therapeutic target for GBM. Furthermore, CRYM may also serve as a promising biomarker for the diagnosis and prognosis of GBM.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Xu Y, Zhao P, Yao Z, et al. CRYM suppresses glioblastoma progression by inhibiting the TGFβ1/Smad-EMT signaling pathway. J Neurooncol. 2026. PMID: 41973277. doi:10.1007/s11060-026-05486-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。